<DOC>
	<DOCNO>NCT00041379</DOCNO>
	<brief_summary>RATIONALE : Biological therapy beta alethine use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I/II trial study effectiveness beta alethine treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>Beta Alethine Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect low-dose beta alethine patient Waldenstrom 's macroglobulinemia . - Determine effect drug anemia , performance status , disease symptom patient . - Determine effect drug immune system patient . - Determine safety drug patient . OUTLINE : This multicenter study . Patients receive beta alethine subcutaneously day 1 , 15 , 29 , 43 , 57 , 71 . Courses repeat every 85 day absence disease progression unacceptable toxicity . Patients follow 30 day . PROJECTED ACCRUAL : A total 13-37 patient accrue study .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis Waldenstrom 's macroglobulinemia Urine serum protein electrophoresis show measurable monoclonal spike Indolent disease yet require therapy allow Positive delayedtype hypersensitivity ( DTH ) response Induration great 2 mm least 1 antigen No clinical sign evidence active brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : At least 4 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Albumin least 3.5 g/dL Bilirubin le 2.0 mg/dL Transaminases great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No acute change EKG No uncontrolled angina No heart failure No arrhythmia Other : Adequate nutritional intake evidence total protein least 60 g/L Not pregnant nursing Fertile patient must use effective contraception No concurrent gastrointestinal bleed No active bacterial infection abscess fistulae HIV negative No concurrent nonmalignant disease would preclude study No history alcoholism , drug addiction , psychotic disorder would preclude followup PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since prior immunotherapy More 4 week since prior cytokine More 4 week since prior plasmapheresis plasma exchange No prior stem cell bone marrow transplant Chemotherapy : More 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , highdose carboplatin ) No prior intensive chemotherapy stem cell support Endocrine therapy : More 4 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : More 4 week since prior radiotherapy involve 25 % bone marrow Surgery : Recovered prior surgery No prior organ transplant Other : No concurrent investigational agent No concurrent immunosuppressants No concurrent antiinflammatory agent include aspirin nonsteroidal antiinflammatory agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>